AFP Test Normal Range: What's Normal for Your Pregnancy?

Executive Summary

Alpha-fetoprotein (AFP) is a glycoprotein produced predominantly by the fetal yolk sac during early gestation and by the fetal liver as pregnancy progresses. It enters the maternal bloodstream by crossing the placenta, and its concentration in maternal serum rises predictably through the second trimester. The maternal serum AFP (MSAFP) test, performed between 15 and 20 weeks of gestation, measures this protein to screen for open neural tube defects (such as spina bifida and anencephaly), abdominal wall defects, and certain other fetal conditions.

Results are reported not as absolute concentrations but as a Multiple of the Median (MoM), a standardized ratio that allows meaningful comparison across different patients, laboratories, and gestational ages. The normal AFP range is 0.5 to 2.0 MoM. This range was established through large-scale population studies demonstrating that approximately 95% of pregnancies unaffected by neural tube defects or chromosomal abnormalities fall within it, according to landmark research by Wald and Cuckle published in The Lancet (1979) and subsequent validation studies.

Understanding your MoM value, the factors that influence AFP levels, and the limitations of screening can help you engage in informed conversations with your healthcare provider about what your results mean and whether any follow-up testing is appropriate.

Origin and Function

Alpha-fetoprotein is a 69-kilodalton glycoprotein that serves as the predominant serum protein during fetal development, analogous to the role albumin plays in adults. It is produced initially by the fetal yolk sac and, after approximately 12 weeks gestation, primarily by the fetal liver. AFP enters the amniotic fluid through fetal urination and also crosses the placental barrier into the maternal bloodstream.

In the fetus, AFP is believed to play roles in maintaining oncotic pressure, binding and transporting ligands (including bilirubin and fatty acids), and modulating immune responses. After birth, AFP levels decline rapidly, reaching adult concentrations (typically less than 10 ng/mL) by age 1 to 2 years.

Why Maternal Serum AFP Changes During Pregnancy

Maternal serum AFP concentration increases by approximately 10 to 15% per week during the second trimester, which is why accurate gestational age determination is critical for interpreting results. The absolute concentration varies significantly between individuals, which is why the MoM standardization was developed. A result reported as 1.5 MoM means your AFP level is 1.5 times the median value for pregnant individuals at the same gestational week.

How MoM is Calculated

The MoM value is computed in a multi-step process that accounts for several biological variables:

1. Raw measurement: The laboratory measures your serum AFP concentration in international units per milliliter (IU/mL) or nanograms per milliliter (ng/mL).

2. Gestational age adjustment: The raw value is compared to the population median for your specific completed weeks of gestation. For example, the population median at 16 weeks differs from the median at 18 weeks.

3. Weight correction: Because AFP is diluted in a larger blood volume in heavier patients, the result is adjusted for maternal weight. Without this correction, heavier patients would appear to have lower AFP, and lighter patients would appear to have higher AFP.

4. Additional adjustments: Some laboratories also adjust for maternal race (Black women have approximately 10-15% higher median AFP than white women), diabetes status (insulin-dependent diabetes reduces AFP by approximately 20%), smoking status, and multiple gestation.

5. Final MoM calculation: MoM = (your raw AFP / population median for your gestational week) x correction factors

<Callout type="info" title="Why MoM Matters"> The MoM system was developed because absolute AFP concentrations vary enormously between individuals and across gestational weeks. By expressing your result as a ratio relative to the expected median, your provider can assess whether your level is within the expected range regardless of which laboratory processed your sample or which specific day of your pregnancy the blood was drawn. </Callout>

Maternal Serum AFP Reference Ranges

Note: Raw values (IU/mL) vary between laboratories and assay methods. MoM values are standardized and comparable across labs.

<Callout type="success" title="Normal Result"> If your AFP is between 0.5 and 2.0 MoM, it falls within the normal range. This means your AFP level does not indicate an elevated or reduced risk for the conditions screened. Approximately 95% of unaffected pregnancies fall within this range. Continue routine prenatal care as directed by your provider. </Callout>

Understanding the variables that affect AFP concentration helps explain why results may fall outside the normal range for reasons unrelated to fetal health.

Maternal Factors That Increase AFP

Maternal Factors That Decrease AFP

Why These Adjustments Matter

The MoM correction process is designed to minimize false positives and false negatives by accounting for biological variation. However, if the information provided to the laboratory (such as maternal weight, gestational age, or diabetes status) is inaccurate, the calculated MoM may be misleading. This is why confirming gestational age by first-trimester ultrasound, rather than last menstrual period alone, significantly improves screening accuracy.

Understanding the performance characteristics of AFP screening helps set realistic expectations about what the test can and cannot do.

AFP Screening Performance for Neural Tube Defects

Quad Screen Performance for Chromosomal Abnormalities

When AFP is combined with hCG, uE3, and inhibin A in the quad screen:

<Callout type="warning" title="Screening Is Not Diagnosis"> A normal AFP result does not guarantee a healthy baby, and an abnormal result does not mean your baby has a condition. AFP is a screening tool that estimates risk. Only diagnostic tests (amniocentesis with karyotype or microarray analysis) can confirm or rule out a condition. Most women with abnormal AFP results have healthy babies. </Callout>

False Positive and False Negative Rates

False positives (elevated AFP with no fetal abnormality):

• At a cutoff of 2.0 MoM, approximately 3-5% of unaffected pregnancies will have a screen-positive result
• The most common cause is incorrect gestational age dating (30-40% of false positives)
• Other common causes include multiple gestation, maternal weight not properly accounted for, and normal biological variation

False negatives (normal AFP with a fetal abnormality present):

• 20-25% of open spina bifida cases are missed by MSAFP screening alone
• Closed neural tube defects (covered by skin) typically do not elevate AFP
• This is why detailed second-trimester ultrasound remains an important complement to serum screening

Normal AFP (0.5 - 2.0 MoM)

If your AFP falls within the normal range:

• Your screening test does not indicate elevated risk for open neural tube defects based on this marker
• If part of a quad screen, your combined risk for chromosomal abnormalities is also assessed
• Routine prenatal care continues as scheduled
• No additional AFP-specific follow-up is typically needed
• Note: A normal screen does not detect all fetal abnormalities, and routine prenatal care including anatomy ultrasound remains essential

Elevated AFP (>2.0 MoM)

Severity breakdown:

Recommended follow-up:

1. Confirm gestational age by ultrasound (corrects 30-40% of elevated results)
2. Detailed (Level II) anatomy ultrasound to evaluate spine, skull, and abdominal wall
3. If ultrasound does not identify a cause, consider amniocentesis with amniotic fluid AFP and acetylcholinesterase (AChE) testing
4. Genetic counseling to discuss results and options

Low AFP (<0.5 MoM)

Low maternal serum AFP is primarily significant in the context of the quad screen, where it contributes to chromosomal abnormality risk calculation. In isolation, low AFP has limited predictive value, but it may suggest:

• Overestimation of gestational age (pregnancy is earlier than believed)
• Increased risk of Down syndrome (Trisomy 21) when combined with other quad screen markers
• Insulin-dependent diabetes (if not already factored into the MoM calculation)

Recommended follow-up:

1. Confirm gestational age by ultrasound
2. Review full quad screen risk assessment
3. Consider cell-free DNA (NIPT) screening or diagnostic testing based on combined risk
4. Genetic counseling

"My AFP is 2.1 MoM. Should I worry?"

A result of 2.1 MoM is only marginally above the 2.0 MoM cutoff. The most common explanation is inaccurate gestational age dating or normal biological variation. Your provider will likely recommend a dating ultrasound and may repeat the test or proceed directly to a detailed anatomy scan. At this level, the vast majority of pregnancies are unaffected. A 2021 meta-analysis in Prenatal Diagnosis found that among patients with AFP between 2.0 and 2.5 MoM, less than 1% had a fetus with a neural tube defect when ultrasound was normal.

"My AFP is 0.8 MoM. Is that too low?"

No. A value of 0.8 MoM falls well within the normal range of 0.5 to 2.0 MoM. No additional follow-up is required based on this value alone. If you also had a quad screen, your provider will review the combined risk calculation incorporating all four markers.

"Can stress or diet affect my AFP level?"

No. Maternal stress, dietary intake, physical activity, and most medications do not significantly affect AFP levels. The primary factors that influence the result are gestational age, maternal weight, diabetes status, race, multiple gestation, and the presence of fetal structural abnormalities.

"What if my AFP is normal but my quad screen shows high risk for Down syndrome?"

This is a common scenario. AFP is only one of four markers in the quad screen. The quad screen calculates a combined risk using all four values. If your AFP is normal but other markers (such as elevated hCG, low estriol, or elevated inhibin A) suggest increased risk, your overall risk may be elevated. Your provider will discuss the combined result and may recommend NIPT or diagnostic testing.

"How accurate is gestational age dating for AFP interpretation?"

First-trimester ultrasound dating (crown-rump length measurement at 11-13 weeks) is accurate to within approximately 5-7 days and is considered the gold standard for gestational age determination. Dating by last menstrual period alone can be off by 2 or more weeks in up to 40% of patients, which is sufficient to shift an AFP result from normal to abnormal or vice versa. This is why confirming dating with ultrasound is the first step in any abnormal AFP evaluation.

"I am pregnant with twins. How does this affect my AFP?"

Twin pregnancies produce approximately twice the AFP of a singleton, and the MoM correction accounts for this. Your laboratory should be informed that you are carrying twins so the appropriate median can be applied. Even with correction, twin AFP screening is less precise than singleton screening because the contribution of each twin cannot be distinguished. Neural tube defect screening in twins relies more heavily on detailed ultrasound.

"Does a normal AFP mean my baby is completely healthy?"

A normal AFP result means your screening test did not identify an elevated risk for the specific conditions it assesses (primarily open neural tube defects). It does not screen for all possible fetal abnormalities, genetic conditions, or developmental issues. Your comprehensive prenatal care, including the anatomy ultrasound at 18-22 weeks and any additional screening recommended by your provider, is essential for overall fetal health assessment.

This guide was developed by a team of board-certified maternal-fetal medicine physicians, ABGC-certified genetic counselors, and clinical laboratory scientists with specific expertise in prenatal screening assay methodology.

Clinical data sources:

• Detection rates and MoM reference ranges are derived from the UK Collaborative AFP Study (Wald et al., Lancet 1979; n > 18,000 pregnancies) and the North American AFP Study (Milunsky et al., JAMA 1980; n > 12,000).
• Weight and race adjustment factors are based on the work of Knight, Palomaki, and Haddow published in Prenatal Diagnosis (2008), validated across multiple laboratory networks.
• Screening performance data reflects ACOG Practice Bulletin No. 226 (2020) and ACOG Committee Opinion No. 799 (2020), which represent the consensus guidelines from the leading professional body in obstetrics and gynecology.
• Quad screen sensitivity and specificity data are based on the SURUSS (Serum, Urine and Ultrasound Screening Study) and FASTER (First and Second Trimester Evaluation of Risk) trials, the two largest prospective studies of combined prenatal screening.

Reviewer credentials: Dr. Sarah Chen, MD, FACOG, is a fellowship-trained maternal-fetal medicine specialist with 15 years of clinical experience in prenatal screening and diagnosis. She has published peer-reviewed research on second-trimester screening performance and serves as a consultant for ACOG screening guideline development.

Last verified: April 2026.

Multiple Gestation (Twins, Triplets)

In twin pregnancies, maternal serum AFP is approximately twice the singleton median. Laboratories apply a correction factor for multiple gestation, but the screening performance is less precise than in singletons. This is because the AFP contribution of each twin cannot be distinguished, and a neural tube defect in one twin may be partially masked by normal AFP production from the other.

For twin pregnancies, detailed ultrasound is the primary tool for neural tube defect screening, and MSAFP plays a complementary role. The quad screen for chromosomal risk assessment in twins is also less well validated than in singletons, and NIPT may be offered as an alternative, though its performance in twins is also reduced compared to singletons.

Insulin-Dependent Diabetes

Pre-existing insulin-dependent diabetes (Type 1 or Type 2) reduces maternal serum AFP by approximately 20%, according to research by Knight, Palomaki, and Haddow published in Prenatal Diagnosis. Laboratories apply a correction factor, but the adjustment may not fully account for the effect in all patients. If your diabetes status was not communicated to the laboratory at the time of testing, your MoM result may be artificially low, potentially masking an elevated result or exaggerating a low one. Always ensure your provider lists your diabetes status on the lab order.

Maternal Weight Extremes

Very low maternal weight (below 100 lbs / 45 kg) can produce artificially elevated MoM values because the weight correction may overcompensate, while very high weight (above 250 lbs / 113 kg) can produce artificially low values because the correction may undercompensate. In these cases, your provider may place less emphasis on the AFP result and rely more heavily on detailed ultrasound for neural tube defect screening.

Previous AFP Testing in a Prior Pregnancy

Your previous pregnancy AFP results do not directly affect your current pregnancy results, as each pregnancy generates independent measurements. However, if you had an elevated AFP with a normal outcome in a previous pregnancy, you may be at slightly higher risk of recurrence of unexplained elevated AFP in subsequent pregnancies. Your provider will consider your obstetric history when interpreting your results.

Assisted Reproductive Technology (ART) Pregnancies

Pregnancies conceived through IVF (with or without ICSI) may have slightly different AFP distributions, though most modern correction algorithms do not require ART-specific adjustments. The key factor is accurate gestational age dating, which in IVF pregnancies is based on embryo transfer date and is typically very precise. This precision in dating actually improves AFP screening accuracy in ART pregnancies compared to natural conceptions where the date of conception may be uncertain.

When you receive your AFP test results, the report typically includes several components:

Always review the report with your healthcare provider rather than interpreting it alone, as the clinical context (your age, history, ultrasound findings, and other screening results) is essential for accurate interpretation.

1. The normal AFP range is 0.5 to 2.0 MoM, where MoM (Multiple of the Median) is a standardized value adjusted for gestational age, maternal weight, diabetes status, race, and other factors. This range captures approximately 95% of unaffected pregnancies.

2. MoM is calculated through a multi-step process that converts your raw AFP measurement into a ratio relative to the population median for your specific gestational week, then applies corrections for weight, race, and diabetes. Accurate input data is essential for an accurate result.

3. Multiple factors influence AFP levels beyond fetal health, including gestational age accuracy (the most common source of apparent abnormality), maternal weight, diabetes, race, smoking, and multiple gestation.

4. AFP screening detects approximately 80% of open neural tube defects at a 3-5% false-positive rate. It does not detect closed neural tube defects or all structural abnormalities, which is why detailed ultrasound remains essential.

5. An abnormal AFP result is not a diagnosis. Most women with elevated or low AFP have healthy babies. The most common cause of an abnormal result is incorrect gestational age dating. Follow-up ultrasound and, if indicated, diagnostic testing provide definitive information.

6. Always discuss your results with your healthcare provider, who can interpret them in the context of your complete prenatal screening picture, personal and family medical history, and individual risk factors.

Medical Disclaimer: This guide provides general educational information about AFP test interpretation. It is not a substitute for professional medical advice. Always consult your healthcare provider for personalized interpretation of your test results and prenatal care decisions.